Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

• Status: Completed
• Trial end date: 2020-10-01

Summary

The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).

• Phase: Phase 2

Details

• Lead Sponsor: Gilead Sciences
• Collaborators: German CLL Study Group; Ono Pharmaceutical Co. Ltd
• Treatments: Obinutuzumab